Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viiv
Biotech
Merck HIV combo pill compares to existing meds in phase 3 trials
The addition of Merck's new oral pill to a cocktail of approved medicines for HIV-1 produced a viral response comparable to common treatments.
Kyle LaHucik
Oct 27, 2021 12:16pm
20-year GSK veteran takes up CSO role at HemoShear
Sep 26, 2019 9:10am
Merck posts 96-week doravirine HIV data as PDUFA date nears
Jul 24, 2018 9:55am
Making inroads toward eliminating HIV
Feb 12, 2018 10:27am
AZ sues exec Luke Miels after his defection to GSK
May 16, 2017 9:52am
PPD supports two pivotal HIV studies through renewed contract with NIH
Mar 8, 2017 9:17am
